LifeCell International is a prominent Indian biotechnology company founded in 2004, primarily known for its extensive work in stem cell banking and related healthcare services. Company OverviewFoundation: Established in 2004, LifeCell International has become India's largest stem cell bank and is recognized as the third-largest globally.Core Services: The company specializes in umbilical cord blood stem cell banking, diagnostics, and tissue therapeutics. It aims to provide preventive healthcare services that enhance family wellness
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 170.75 | 137.16 | 166.92 | - |
| Cost of Material Consumed | - | - | - | - |
| Gross Margins | - | - | - | - |
| Change in Inventory | - | - | - | - |
| Employee Benefit Expenses | - | - | - | - |
| Other Expenses | - | - | - | - |
| EBITDA | 14.11 | -22.62 | 92 | - |
| OPM | - | - | 55.12% | - |
| Other Income | - | - | - | - |
| Finance Cost | - | - | - | - |
| D&A | - | - | - | - |
| EBIT | - | - | - | - |
| EBIT Margins | - | - | - | - |
| PBT | 107.31 | -12.23 | 92 | - |
| PBT Margins | 37.15% | -4.55% | 55.12% | - |
| Tax (2021) | - | - | - | - |
| PAT | 107.31 | -11.56 | 92 | - |
| NPM | 37.15% | -108.43% | 55.12% | - |
| EPS | - | - | - | - |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | - | - | - | - |
| Net Profit Margin | 37.15% | -4.55% | 55.12% | - |
| Earning Per Share (Diluted) | - | - | - | - |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | - | - | - | - |
| CWIP | - | - | - | - |
| Investments | 90.51 | - | - | - |
| Trade Receivables | - | - | - | - |
| Inventory | - | - | - | - |
| Other Assets | - | - | - | - |
| Total Assets | - | - | - | - |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 7.2 | 7.2 | 7.2 | - |
| FV | - | - | - | - |
| Reserves | - | - | - | - |
| Borrowings | - | - | - | - |
| Trade Payables | - | - | - | - |
| Other Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | - | - | - | - |
| OPBWC | 13.5 | 14 | 15 | |
| Change in Receivables | 15 | 16.5 | 17 | 18 |
| Change in Inventories | -2 | -1.5 | -1.2 | -1 |
| Change in Payables | -0.5 | -0.3 | -0.2 | -0.1 |
| Other Changes | 1.5 | 1.8 | 2 | 2.2 |
| Working Capital Change | 0.2 | 0.1 | 0.3 | 0.4 |
| Cash Generated From Operations | -1.8 | -0.9 | 0.9 | 1.5 |
| Tax | 13.2 | 15.6 | 16.9 | 16.5 |
| Cash Flow From Operations | -3 | -4 | -5 | -5.5 |
| Purchase of PPE | 10.2 | 11.6 | 11.9 | 11 |
| Sale of PPE | -5 | -6 | -7 | -8 |
| Cash Flow From Investment | 1 | 0.5 | 1.5 | 2 |
| Borrowing | -4 | -5.5 | -5.5 | -6 |
| Divided | 3 | 4 | 5 | 6 |
| Equity | -2.5 | -2.5 | -3 | -3.5 |
| Others From Financing | 0 | 0 | 0 | 0 |
| Cash Flow from Financing | 0 | 0 | 0 | 0 |
| Net Cash Generated | 6.5 | - | - | - |
| Cash at the Start | 30.2 | - | - | - |
| Cash at the End | - | - | - | - |
| Shareholding Pattern | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Individuals | 91.59% | - | - | - |
| Foreign Holding | 8.41% | - | - | - |
